You just read:

Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease

News provided by

Genomic Health, Inc.

May 12, 2017, 12:48 ET